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Background: Capecitabine has activity against several types of cancer. In 10-15% of patients treated with capecitabine,
treatment is discontinued because of serious adverse reactions, mostly within the first weeks of treatment.
Case presentation: A 56 year-old female patient presented at the emergency department after ten days of
chemotherapy with progressive airway obstruction and complaints of numbness of the tongue. She also had difficulty
swallowing and was unable to speak. Laboratory findings were completely normal and no co-medication was used, in
particular no dopamine antagonists.
A diagnosis of oromandibular dystonia due to capecitabine use was made. After the anticholinergic drug biperiden
(Akineton) was given intravenously, complaints disappeared within twenty minutes. Due to an early discontinuation of
biperiden, however, the symptoms of oromandibular dystonia recurred. Again, she was successfully treated with an
anticholinergic drug. Capecitabine was permanently discontinued. Three days after the initial presentation the
anticholinergic drug was stopped after which symptoms did not reappear.
Conclusion: The case highlights the need for awareness that capecitabine may potentially lead to severe
life-threatening complaints of oromandibular dystonia. We hypothesize that capecitabine passed the blood
brain barrier which led to a disruption within the basal ganglia in this case. Prompt treatment with an anticholinergic
drug and cessation of capecitabine in the patient case led to disappearance of complaints.
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Capecitabine has proven activity against several types of
cancers, including those of the gastro-intestinal tract,
and breast. It is an oral prodrug that is converted to its
active metabolite 5-fluorouracil (5-FU). Together with
tegafur, which is another oral prodrug, and 5-FU itself,
capecitabine belongs to the group of fluoropyrimidines.
Common dose-limiting systemic toxicities are hand-foot
syndrome and diarrhoea. Because the final converting
step of capecitabine to 5-FU is believed to take mainly
place in the tumour, side effects of capecitabine are pre-
sumably less than with 5-FU [1]. However, in 10%-15%
of the patients treated with capecitabine treatment is
discontinued because of adverse reactions [2,3]. Most of* Correspondence: j.sprangers@erasmusmc.nl
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this article, unless otherwise stated.these discontinuations are necessary within the first
weeks of treatment [3]. Here, we present a rare but
serious case of severe oromandibular dystonia shortly
after starting capecitabine.
Case presentation
A 56 year-old Caucasian woman who was diagnosed
with a T3N2M0 rectal cancer, underwent neoadjuvant
chemoradiotherapy with capecitabine. She presented at
the emergency department after ten days of treatment
with capecitabine (1,500 mg BID).
During the six days prior to presentation, she devel-
oped progressive symptoms of cramps between her
shoulders, a tingling feeling in both arms and numbness
of the tongue. She also had difficulty swallowing and
was unable to speak. Symptoms were intermittent, but
progressive during these six days, leading to progressive
airway obstruction at the day of presentation. She did
not have any features of typical capecitabine toxicity likeed Central. This is an Open Access article distributed under the terms of the
://creativecommons.org/licenses/by/4.0), which permits unrestricted use,
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other focal neurological signs. Laboratory findings were
completely normal and no co-medication was used, in
particular no dopamine antagonists.
A diagnosis of oromandibular dystonia due to capecit-
abine use was made, and the drug was stopped immedi-
ately. The anticholinergic drug biperiden (Akineton) 10
mg was given intravenously, after which speaking and
tongue movements improved within twenty minutes.
Unfortunately, despite prescription of biperiden 5 mg,
it was inadvertently not given, and twelve hours after
presentation the symptoms of oromandibular dystonia
with difficult speaking and tongue numbness recurred in
the same intensity as at presentation. Again, she was
successfully treated with biperiden intravenously.
After the patient was able to swallow again, a switch
to an oral anticholinergic (1 mg of trihexyfenidyl
(Artane) once daily) was made during three days. Symp-
toms did not reappear and the patient was successfully
discharged from the hospital. Pharmacogenetic counsel-
ing, performed after the side effect appeared, showed a
DPYD *1/*1 genotype, which corresponds to a normal
5-FU drug metabolism.
Discussion
We report an extremely rare, but clinically highly rele-
vant, case of capecitabine induced oromandibular dys-
tonia, leading to progressive airway obstruction without
any other associated neurological signs. We concluded
that this was due to capecitabine use, because after dis-
continuing bipiriden treatment for the acute dystonia,Table 1 The Naranjo Causality Scale
1. Are there previous conclusive reports on this reaction?
2. Did the adverse event occur after the suspected drug was administered?
3. Did the adverse reaction improve when the drug was discontinued or a sp
4. Did the adverse reaction reappear when the drugs was readministered? (‘r
5. Are there alternative causes (other than the drug) that could have on their
6. Did the reaction reappear when a placebo was given?
7. Was the blood detected in any body fluid in toxic concentrations?
8. Was the reaction more severe when the dose was increased, or less severe
9. Did the patient have a similar reaction to the same or similar drugs in any
10. Was the adverse event confirmed by any objective evidence?
Scoring
≥9 = definite ADR
5-8 = probable ADR
1-4 = possible ADR
0 = doubtful ADR
*We answered this question with ‘yes’. Although capecitabine was not readminister
to the side-effects of capecitabine and its metabolites which in all probability had nsymptoms reappeared, which may be seen as a rechal-
lenge phenomenon and after cessation of capecitabine
she recovered completely and complaints never re-
curred. Moreover, the assessment by the Naranjo causal-
ity scale – a method for estimating the probability of
adverse drug reactions – [4] showed that the adverse
drug reaction was definitely related to the drug (see
Table 1). Furthermore, other – rare – causes of oroman-
dibular dystonia, such as the use of metoclopramide,
were excluded.
Our case is the first reported case of oromandibular
dystonia due to capecitabine in Caucasians. In an earlier
described case a Chinese male patient developed oro-
mandibular dystonia nine days after swallowing capecita-
bine which resolved spontaneously after three days [5].
However, a feeding tube had to be inserted because he
had difficulty swallowing during these days. To the best
of our knowledge oromandibular dystonia is never re-
ported after the administration of other forms of 5-FU.
Focal dystonia, however, caused by 5-FU has been re-
ported in one earlier case series including three cases
[6]. Due to the serious nature of this adverse event,
although rare, we are convinced that physicians should
be aware of this.
Fluoropyrimidine toxicity can be predicted by certain
pharmacogenetic markers [7]. A main marker is dihy-
dropyrimidine dehydrogenase (DPD) [8]. DPD is the
rate-limiting enzyme for fluoropyrimidine catabolism
that eliminates >80% of administered 5-fluorouracil [9].
The most predominant polymorphism associated with
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echallenge’) +2 −1 0 +2*
own caused the reaction? −1 +2 0 +2
−1 +1 0 0
+1 0 0 0
when the dose was decreased? +1 0 0 0
previous exposure? +1 0 0 0
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ed, biperiden was discontinued. By doing so, the patient could be re-exposed
ot been completely eliminated.
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reported here is due to DPD deficiency [8].
It is thought that abnormalities in neurotransmitters
resulting in disturbed firing patterns of the basal ganglia
are involved in the case of oromandibular dystonia [11].
The pathophysiological mechanism by which oroman-
dibular dystonia occurs upon capecitabine intake is un-
clear. One plausible explanation is that capecitabine may
pass through the blood brain barrier [5], which may lead
to a disruption within the basal ganglia, the centre for
movement control. Such disruption is seen with other
types of dystonia and other causes of oromandibular
dystonia [12-14]. The rapid improvement after anti-
cholinergic drugs, which is the first choice of systemic
treatment in these other types of dystonia [15], under-
lines a similar pathogenesis. That capecitabine may
pass through the blood brain barrier is affirmed by its
activity in patients with brain metastases from breast
cancer [16], together with other reported capecitabine
central nervous system toxicity, such as cerebellar
toxicity [17].Conclusion
Our case highlights the need for awareness that capecit-
abine may potentially lead to severe life-threatening
complaints of oromandibular dystonia. More research is
needed to clarify the pathogenesis of oromandibular dys-
tonia in case of capecitabine intake. When faced with a
patient with oromandibular dystonia we suggest prompt
treatment with an anticholinergic drug, such as bipiri-
den, and cessation of capecitabine.Consent
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